SPH Xing Ling Science & Technology Pharmaceutical

SPH Xing Ling Science & Technology Pharmaceutical (SPH Xing Ling) is a prominent subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd., specializing in the modernization of Traditional Chinese Medicine (TCM) and natural products. Founded in 1998 and headquartered in Shanghai, the company is a leader in the production of standardized Ginkgo biloba extracts and artificial musk. Its flagship products, including Ginkgo Ketone Ester and Artificial Musk (Haikesu I and II), are widely used in treating cardiovascular and cerebrovascular diseases. SPH Xing Ling is recognized for its advanced manufacturing capabilities, having established a 'Lighthouse Factory' that integrates automation, digitalization, and green production practices. The company maintains a strong focus on R&D, collaborating with academic institutions to explore new therapeutic applications for its botanical extracts in areas such as cognitive impairment and myocardial protection.